倍他乐克联合胺碘酮治疗顽固性室性早搏的疗效分析(1)
摘 要：目的 探讨倍他乐克联合胺碘酮治疗顽固性室性早搏的临床疗效及安全性。方法 选择我院2016年1月～2017年1月收治的顽固性室性早搏患者108例。按随机数字表法分为观察组和对照组，各54例，观察组采用常规治疗加用倍他乐克及胺碘酮口服，对照组则采用常规治疗加用倍他乐克口服，观察两组患者的临床疗效及安全性。结果 观察组总有效率为96.30%高于对照组的79.63%，差异有统计学意义(P<0.05)，且观察组治疗后室性早搏、心率及左室射血分数得到改善，改善水平优于对照组(P<0.05)。观察组不良反应发生率9.26%与对照组7.41%，差异无统计学意义(P>0.05)。结论 倍他乐克联合胺碘酮治疗顽固性室性早搏疗效显著，安全性好，是治疗顽固性室性早搏的最佳选择。
关键词：倍他乐克;胺腆酮;室性早搏
中图分类号：R541.7 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.05.045
, http://www.100md.com
文章编号：1006-1959(2018)05-0128-03
Efficacy of Betaloc Combined with Amiodarone in the Treatment of Intractable Ventricular Premature Beats
ZHANG Hua-guang
(Department of Cardiology，Bobai People's Hospital，Bobai 537600，Guangxi，China)
Abstract：Objective To investigate the clinical efficacy and safety of betaloc combined with amiodarone in the treatment of intractable ventricular premature beats.Methods 108 patients with intractable ventricular premature beats from January 2016 to January 2017 were selected.According to the digital table method they were divided into observation group and control group，54 cases each，the observation group was treated with routine therapy and betaloc and amiodarone，while the control group was treated with routine therapy and betaloc orally.The clinical efficacy and safety of the two groups were observed.Results The total effective rate of the observation group was 96.30% higher than that of the control group 79.63%，the difference was statistically significant(P<0.05)，and the ventricular premature beat，heart rate and left ventricular ejection fraction were improved after treatment in the observation group，the improvement level was better than that in the control group(P<0.05)，the incidence of adverse reactions in the observation group was 9.26% and that in the control group was 7.41%，there was no significant difference between the two groups(P>0.05).Conclusion Betaloc combined with amiodarone in the treatment of intractable ventricular premature beats is the best choice for the treatment of intractable ventricular premature beats.
, 百拇医药
Key words：Betaloc;Amine;Ventricular premature beat
室性早搏(或室性期前收縮)，简称室早(ventricular premature beats，VPBs)，是各种器质性心脏病患者的最常见并发症，是室性心律失常的一种类型，也是临床最常见的心律失常之一和治疗的一大难题，轻者可无症状或感心悸、气短、胸闷不适，重者可引起短阵持续性室性心动过速甚至危及生命。临床上把病程长、发作频繁及治疗效果不佳的室性早搏统称为顽固性或难治性室性早搏。目前室性早搏治疗仍以药物治疗为主，本研究选择2016年1月～2017年1月收治已接受心律平、慢心律等相关药物治疗且疗效欠佳的顽性室性早搏患者108例，应用倍他乐克联合胺碘酮治疗顽固性室性早搏，探讨其临床疗效及安全性，现报告如下。, 百拇医药(张华光)
关键词：倍他乐克;胺腆酮;室性早搏
中图分类号：R541.7 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.05.045
, http://www.100md.com
文章编号：1006-1959(2018)05-0128-03
Efficacy of Betaloc Combined with Amiodarone in the Treatment of Intractable Ventricular Premature Beats
ZHANG Hua-guang
(Department of Cardiology，Bobai People's Hospital，Bobai 537600，Guangxi，China)
Abstract：Objective To investigate the clinical efficacy and safety of betaloc combined with amiodarone in the treatment of intractable ventricular premature beats.Methods 108 patients with intractable ventricular premature beats from January 2016 to January 2017 were selected.According to the digital table method they were divided into observation group and control group，54 cases each，the observation group was treated with routine therapy and betaloc and amiodarone，while the control group was treated with routine therapy and betaloc orally.The clinical efficacy and safety of the two groups were observed.Results The total effective rate of the observation group was 96.30% higher than that of the control group 79.63%，the difference was statistically significant(P<0.05)，and the ventricular premature beat，heart rate and left ventricular ejection fraction were improved after treatment in the observation group，the improvement level was better than that in the control group(P<0.05)，the incidence of adverse reactions in the observation group was 9.26% and that in the control group was 7.41%，there was no significant difference between the two groups(P>0.05).Conclusion Betaloc combined with amiodarone in the treatment of intractable ventricular premature beats is the best choice for the treatment of intractable ventricular premature beats.
, 百拇医药
Key words：Betaloc;Amine;Ventricular premature beat
室性早搏(或室性期前收縮)，简称室早(ventricular premature beats，VPBs)，是各种器质性心脏病患者的最常见并发症，是室性心律失常的一种类型，也是临床最常见的心律失常之一和治疗的一大难题，轻者可无症状或感心悸、气短、胸闷不适，重者可引起短阵持续性室性心动过速甚至危及生命。临床上把病程长、发作频繁及治疗效果不佳的室性早搏统称为顽固性或难治性室性早搏。目前室性早搏治疗仍以药物治疗为主，本研究选择2016年1月～2017年1月收治已接受心律平、慢心律等相关药物治疗且疗效欠佳的顽性室性早搏患者108例，应用倍他乐克联合胺碘酮治疗顽固性室性早搏，探讨其临床疗效及安全性，现报告如下。, 百拇医药(张华光)